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p53 activation by ribosomal biogenesis stress is important for tumor suppression. In the August issue of
Nature Medicine, Sasaki et al. identify PICT1 as a regulator of this process. PICT1 sequesters ribosomal
protein RPL11 in the nucleolus, attenuating p53 induction. Excessive PICT1 may dampen the p53 response
and promote cancer.Ribosome biogenesis, the elaborate pro-
cess of ribosome production, is tightly
connected to cell growth and cell pro-
liferation. Its deregulation has been impli-
cated in a multitude of human pathologies
(Narla and Ebert, 2010) and can also
contribute to cancer. The cell’s nucleolus
acts as a hub for ribosome biogenesis. In
recent years, the role of the nucleolus as
a stress sensor has gradually been un-
folding. In particular, many types of stress
signals converge on the nucleolus to acti-
vate the tumor suppressor p53 (Boulon
et al., 2010). Specifically, a group of ribo-
somal proteins (RPs), including RPL5,
RPL11, RPL23 and RPS7, serve as stress
signal transmitters; following stress, they
are released from the nucleolus, bind
Mdm2, and activate p53 (Zhang and Lu,
2009).
The Mdm2 E3 ubiquitin ligase is a piv-
otal negative regulator of p53 (Michael
and Oren, 2003). In nonstressed cells,
Mdm2 maintains constitutively low p53
levels. Upon stress, a variety of molecular
mechanisms converge to abrogate the
inhibitory effects of Mdm2, thereby
enabling p53 accumulation and unleash-
ing p53-mediated biological responses,
including growth arrest, senescence,
and apoptosis (Michael and Oren, 2003).
As noted above, a variety of ribosomal
proteins can bind directly to Mdm2 and
quench its ability to promote p53 ubiquity-
lation and degradation, thus triggering
a p53 response (Zhang and Lu, 2009).
The physiological importance of this regu-
latory axis was recently demonstrated in
mice expressing an Mdm2 mutant that
cannot bind RPL5 and RPL11 (Macias
et al., 2010). Cells cultured from such
mice failed to mount a p53 response
upon disruption of ribosomal biogenesis.Notably, the mice succumbed more rap-
idly to lymphoma. Better understanding
of the molecular mechanisms governing
the RPs-Mdm2-p53 axis might therefore
provide clues toward improved cancer
diagnostics and prognostics and possibly
also novel therapeutic strategies.
Recent work by Sasaki et al. (2011)
identifies PICT1 as a new pivotal regulator
of this axis. To elucidate the biological
functions of PICT1, Sasaki et al. attemp-
ted to produce Pict1 knockout mice,
only to discover that Pict1 loss was lethal
in early embryogenesis, owing to apo-
ptotic cell death and growth inhibition.
To circumvent this problem, they gener-
ated a ‘‘switchable’’ Pict1 embryonic
stem cell model and found that the
adverse effects observed following Pict1
ablation were due to excessive p53 acti-
vation. Similar p53-dependent effects
were observed in thymuses of mice with
conditional Pict1 inactivation as well as
in cultured cancer cell lines.
To elucidate themolecular basis for p53
activation upon PICT1 depletion, Sasaki
et al. (2011) undertook a proteomics
approach and found that PICT1, which
resides primarily in the nucleolus, can
bind numerous ribosomal proteins, in-
cluding RPL5 and RPL11. Interestingly,
PICT1 depletion caused translocation of
RPL11, but not of other RPs, from the
nucleolus into the nucleoplasm, implying
that PICT1 was specifically required for
nucleolar anchoring of RPL11. Moreover,
knockdown of RPL11, but not of other
RPs, attenuated the accumulation of p53
upon PICT1 loss. Further analysis con-
firmed that in the absence of PICT1, the
translocated RPL11 engagedMdm2with-
in the nucleoplasm and inactivated it,
leading to p53 stabilization and accumu-Cancer Cell 20, Selation. The picture that emerges from
these findings (Figure 1) is that PICT1 nor-
mally retains RPL11 in the nucleolus,
thereby dampening the induction of p53
by ribosomal biogenesis stress and pos-
sibly additional types of stress that rely
on inhibition of Mdm2 by free RPL11.
This may set a threshold that prevents
spurious p53 activation by physiological
fluctuations in the rate of ribosomal bio-
genesis. Conceivably, excessive nucle-
olar PICT1 might hinder the cell’s ability
to mount an efficient p53 response, po-
tentially promoting neoplastic processes.
Of note, in cancer cells, ribosome biogen-
esis is often deregulated and aberrantly
augmented, presumably placing cells
under constant ribosomal stress. Ele-
vated levels of PICT1 might enable such
cells to cope with the chronic stress by
retaining RPL11 more avidly in the nucle-
olus, thus quenching p53 activation
(Figure 1). In line with this conjecture, in
several human cancers high PICT1 levels
were found to correlate with worse prog-
nosis, particularly in tumors that retain
wild-type p53, whereas reduced Pict1
expression delayed tumor progression
in a mouse skin cancer model (Sasaki
et al., 2011).
These findings position PICT1 as a
potentially important new regulator of
p53 function, whose deregulation can
impact cancer development. They also
raise many questions that remain to be
answered. For instance, can excessively
high levels of PICT1 actively drive tumori-
genesis, similar to Mdm2 and its relative
Mdmx/Mdm4? Is the PICT1 gene ampli-
fied or otherwise aberrantly hyperacti-
vated in human tumors? And how is the
restraining effect of PICT1 over RPL11
relieved under conditions of ribosomalptember 13, 2011 ª2011 Elsevier Inc. 283
Figure 1. Regulation of p53 Activity and p53-Dependent Biological Outcomes by PICT1
PICT1 binds and retains RPL11 in the nucleolus, thereby enabling Mdm2 to inhibit p53 to ensure low basal
p53 activity (left). When normal cells are confronted with ribosome biogenesis stress, PICT1 levels drop,
releasing RPL11 into the nucleoplasm (middle). Other mechanisms, such as posttranslational modifica-
tions, might also facilitate RPL11 release. Within the nucleoplasm, free RPL11 binds and inactivates
Mdm2, promoting p53 accumulation and activation (middle). In some cancer cells, elevated PICT1 levels
may retain RPL11 more avidly in the nucleolus, thereby restricting p53 activation and enabling better
coping with chronic stress associated with neoplastic transformation (right).
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effective p53 activation? Are stress-
induced posttranslational modifications
involved in such regulation? Furthermore,
is the role of PICT1 unique, or is there
a larger group of functionally similar
nucleolar proteins that retain other ribo-
somal protein? With regard to the regula-
tion of PICT1 by ribosomal biogenesis
stress, Sasaki et al. (2011) do provide at
least one important clue by showing that
PICT1 protein levels decrease following
treatment with drugs that induce such
stress.
Finally, one interesting question raised
by the findings of Sasaki et al. is what
makes a gene qualify as a tumor sup-
pressor. While PICT1 has previously284 Cancer Cell 20, September 13, 2011 ª20been implicated as a tumor suppressor
in glioma and ovarian cancer (Kim et al.,
2008; Merritt et al., 2009), data from Sa-
saki et al. (2011) point in the opposite
direction, invoking instead an oncogenic
role for PICT1. The fact that PICT1 deple-
tion unleashes a p53 response seemingly
argues unequivocally in favor of the latter
conjecture. But this is not necessarily so.
In fact, p53 is a rather avid ‘‘guardian of
tumor suppressors,’’ activated when
other tumor suppressors become defunct
and presumably providing the cell with
a safety net against cancer, as nicely
exemplified for pRB and PTEN (Chen
et al., 2005; Macleod et al., 1996). More-
over, similar to pRB ablation, PICT1 abla-
tion induces expression of ARF (Sasaki11 Elsevier Inc.et al., 2011), considered indicative of
excessive mitogenic signaling. Yet, the
delayed development of skin tumors in
Pict1+/ mice and the better prognosis
of patients with colorectal and esopha-
geal tumors expressing low PICT1 levels
(Sasaki et al., 2011) do imply that at least
in those cancer types, PICT1 has onco-
genic rather than tumor suppressor attri-
butes. Figuring out what dictates whether
deregulated PICT1 promotes or inhibits
cancer is an open challenge for the future.REFERENCES
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